Glucagon Market Size, Share, Growth Report [2024-2033]

Glucagon Market Research, 2033

The global glucagon market size was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033. the growing awareness of hypoglycemia management, as healthcare providers and patients become more conscious of the importance of having emergency treatments like glucagon readily available
Glucagon Market

Market Introduction and Definition

Glucagon is a peptide hormone produced by the alpha cells of the pancreas, primarily responsible for raising blood glucose levels. It acts as a counter-regulatory hormone to insulin. When blood sugar levels drop, glucagon is released, triggering the liver to convert stored glycogen into glucose through glycogenolysis. It also promotes gluconeogenesis, where the liver generates glucose from non-carbohydrate sources. This process increases glucose availability for energy, particularly during fasting or hypoglycemia. Glucagon is used therapeutically to treat severe hypoglycemia, especially in diabetic patients, and for diagnostic purposes in certain medical conditions.

Key Takeaways

The glucagon market share study covers 20 countries. The research includes a segment analysis of each country in terms of value ($Billion) for the projected glucagon market forecast period 2024-2033.
More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major glucagon industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.

Key Market Dynamics

The glucagon market growth is driven by several critical factors. One of the primary drivers is the rising prevalence of diabetes worldwide, which has significantly increased the demand for glucagon, particularly in managing severe hypoglycemia, a common complication among diabetic patients. Additionally, technological advancements in glucagon delivery methods, such as autoinjectors and nasal sprays, have improved the convenience and usability of glucagon treatments, further boosting market growth. Furthermore, glucagon's expanding applications beyond hypoglycemia treatment, such as its use in diagnostic procedures and treating cardiogenic shock, have contributed to the growing demand.

However, despite these growth drivers, several restraints limit the glucagon market. The high cost of glucagon treatments remains a significant barrier, particularly in lower-income regions, where access to life-saving medications is limited. Additionally, side effects associated with glucagon use, such as nausea and vomiting, may deter some patients from using it. Another restraint is the lack of awareness in developing countries about hypoglycemia management, where healthcare systems may be underdeveloped, limiting the availability and use of glucagon. Furthermore, glucagon's complex storage requirements, including the need for proper temperature control, can present logistical challenges for distribution and shelf life, particularly in resource-constrained settings.

However, there are key opportunities in the glucagon market growth. The development of novel glucagon formulations and analogues could overcome the storage and administration challenges, making the product more accessible. Additionally, the increasing demand for glucagon in emerging markets, coupled with government initiatives supporting diabetes management and hypoglycemia awareness, offers significant growth potential for the glucagon market.

Diabetes prevalence estimates (2030)

According to the International Diabetes Federation, the estimated prevalence of diabetes among individuals aged 20-79 in 2030 highlights significant concerns, with the U.S. projected at 34, 755.3 thousand cases, the UK at 4, 140.6 thousand, India at 92, 973.7 thousand, and Spain at 5, 576 thousand. This rising prevalence, particularly in populous countries like India, underscores the urgent need for effective diabetes management solutions, including glucagon for severe hypoglycemia. As diabetes cases increase, the demand for glucagon will rise correspondingly, driving market growth as patients and healthcare providers seek reliable emergency treatments to manage blood sugar levels effectively.

Diabetes prevalance estimates (2030)- Thousands

Country	2030
U.S.	34755.3
UK	4140.6
India	92973.7
Spain	5576

Source : International Diabetes Federation

Market Segmentation

The glucagon industry is segmented into type, application, distribution channel and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, the market is segmented into hypoglycemia and diagnostic aid. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional/Country Market Outlook

The glucagon market size exhibits strong regional growth, particularly in North America, driven by high diabetes prevalence, advanced healthcare infrastructure, and widespread awareness of hypoglycemia management. The U.S. leads the market due to robust demand for innovative glucagon formulations and devices. In Europe, countries like Germany, the UK, and France are key contributors, supported by well-established healthcare systems and increasing diabetes cases. Asia-Pacific is expected to witness the fastest growth, particularly in China and India, due to rising diabetes incidence and expanding healthcare access. However, limited awareness and high costs remain challenges in Latin America and Africa, constraining market growth.

Industry Trends

UnitedHealthcare will eliminate out-of-pocket costs in standard fully insured group plans for certain preferred prescription drugs, including insulin and several drugs used to treat emergencies such as severe allergic reactions, hypoglycemia, opioid overdoses, and acute asthma attacks. This new standard offering has been made available to group fully insured plans from January 1, 2023, subjected to any required regulatory approval.

Competitive Landscape

The major players operating in the glucagon market share include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc., United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Corteva Agriscience, and Amgen Inc.

Recent Key Strategies and Developments

In May 2024, Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending granting marketing authorization for dasiglucagon solution for injection in the treatment of severe hypoglycemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
In April 2023, Eli Lilly and Company and Amphastar Pharmaceuticals, Inc., announced a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

Key Sources Referred

International Diabetes Federation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
American Diabetes Association (ADA)
Diabetes Canada
Asian Association for the Study of Diabetes (AASD)
Australian Diabetes Society (ADS)
World Obesity Federation
OECD Health Statistics
Juvenile Diabetes Research Foundation
European Association for the Study of Diabetes (EASD)

Key Benefits for Stakeholders

This report provides a quantitative analysis of the glucagon market segments, current trends, estimations, and dynamics of the glucagon market analysis from 2023 to 2033 to identify the prevailing glucagon market opportunity.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the glucagon market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global glucagon market statistics.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global glucagon market trends, key players, market segments, product type areas, and market growth strategies.

Glucagon Market , by Product Type Report Highlights

Aspects	Details
Market Size By 2033	USD 0.6 Billion
Growth Rate	CAGR of 6.4%
Forecast period	2024 - 2033
Report Pages	216
By Product Type	Injectable Glucagon Nasal Glucagon
By Application	Hypoglycemia Diagnostic Aid
By Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	United Biotech (P) Limited, Zealand Pharma A/S, Pfizer Inc., Amphastar Pharmaceuticals, Inc., Taj Pharmaceuticals Limited, Novo Nordisk A/S, Fresenius SE & Co. KGaA, ILS Inc, Eli Lilly and Company., Xeris Biopharma Holdings, Inc.